Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
The FDA supports a biomarker for aggressive fibrotic tumors
Source: Nordic Bio The FDA has granted its backing to a blood test that may be able to determine if ...
AbbVie claims that Coherus violated the Humira patent settlement by working with Mark Cuban’s pharmaceutical company
AbbVie says that Coherus breached a licensing agreement that controls the commercialization of the biosimilar in a regulatory filing. The ...
FDA committee to talk about choosing the right strain for the subsequent round of COVID-19 boosts
Source – FDA The FDA’s Advisory Committee on Vaccines and Related Biological Products will meet on 15 June to discuss ...
Ex-baseball player hired by AbbVie to help de-stigmatize bowel condition as part of their post-Humira growth strategy
In his second season playing professional baseball, Fowler, who won the World Series with the Chicago Cubs in 2016, had ...
In a heated dispute over blood cancer treatment, AbbVie sues BeiGene over a brand-new Imbruvica patent
AbbVie’s Pharmacyclics division claims that BeiGene’s Bruki Nsa violates a patent on its blood cancer medication Imbruvica in a recent ...
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL
Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...
LIPITOR: The Unprecedented Success Story of the Most Profitable Drug in Pharmaceutical History
In the pharmaceutical landscape, certain drugs have achieved unparalleled success in terms of profitability, with LIPITOR standing out as the ...
Ziftomenib: A Promising New Treatment for NPM1-Mutated Acute Myeloid Leukemia
Kura Oncology’s recent presentation at the European Hematology Association (EHA) 2023 conference highlighted the impressive clinical potential of ziftomenib in ...
The Impact of CD38 Multiple Myeloma Treatment: A Comprehensive Analysis
Introduction The landscape of multiple myeloma treatment has witnessed a significant breakthrough with the advent of CD38 Multiple Myeloma Treatment ...
98% ORR in Early-Stage Classical Hodgkin Lymphoma with Brentuximab Vedotin + Nivolumab/Chemo
Source – Seagen Frontline treatment with the combination of brentuximab vedotin (Adcetris), nivolumab (Opdivo), doxorubicin, and dacarbazine led to an ...
FDA Prolongates PDUFA Nirogacestat’s NDA for desmoid tumors is three months
Source – SpringWorks According to SpringWorks Therapeutics on June 7, 2023, the FDA has extended the Prescription Drug User Fee ...
Clinical Activity is Induced by Ziftomenib in NPM1-mutant R/R AML
Source – Kura Oncology Phase I data from the KOMET-001 trial (NCT04067336) showed that treatment with Ziftomenib, a menin-MLL (KMT2A) ...
Companion Diagnostic for Encorafenib + Cetuximab in BRAF V600E alteration in mCRC Receives FDA Approval
Source – Foundation Medicine In order to identify patients with metastatic colorectal cancer (mCRC) who could be candidates to receive ...
Kura makes a $100 million offer when AML is caused by a Menin inhibitor
Source – Kura Oncology Safety problems had previously slowed down the development of Kura Oncology’s Menin inhibitor Ziftomenib for acute ...
Trial of 2seventy Bio’s AML cell treatment was put on hold following a death
Source – 2seventy bio On June 14, 2023, as a result of Seattle Children’s Therapeutics pausing a clinical study of ...
To support women’s health programmes in Latin America and the Caribbean, Organon partners with a bank
Source: Organon Organon, a women’s health company, set objectives for increasing access to healthcare last summer in its inaugural environmental, ...
Acadia plans a Phase III study for a Prader-Willi syndrome candidate following an FDA meeting
Source – Acadia Pharmaceuticals ACP-101, also known as intranasal carbetocin, has been chosen by Acadia to move forward into a ...
Pfizer updates papers for its $43 billion acquisition of Seagen as the FTC keeps a watch on biopharma M&A deals
Source: Pfizer A month later, Pfizer withdrew its notice for its proposed $43 billion acquisition of cancer medication expert Seagen ...
2023 EASL Congress: Gilead to Present New Liver Disease Research
According to Gilead Sciences new data will be presented at the 2023 European Association for the Study of the Liver ...
Sanofi Consumer Healthcare introduces a new site to advance science and address significant self-care issues
Source – Sanofi On June 15, a new Open Innovation Portal was made available by Sanofi’s Consumer Healthcare Business Unit, ...
To speed up patient access to Biosimilar medications, Sandoz announces the Act4 Biosimilars Action Plan
Source – Novartis On June 15, a global plan to improve patient access to biologic medicines was launched, according to ...
Unleashing the Future of Pharma: introduction Of AI in Pharmaceutical industry
The pharmaceutical industry has not been exempt from the revolution that artificial intelligence (AI) has brought about in other industries. ...
Another Stelara patent settlement was reached by J&J, this time with Alvotech and Teva
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar ...
In Germany, a COVID-19 vaccine damage claim will be defended by BioNTech
Source- BioNTech The COVID-19 vaccine partner of Pfizer, BioNTech, is going to court in its native Germany to defend itself ...
Healthware Group and Digital Therapeutics Alliance launch website and DTx policy report
Source – Healthware Group On 9 June 2023, the European DTx Policy Coalition was established by Healthware Group and the ...
Astellas Faces Setback in the US Patent Trial for Myrbetriq
Source – Astellas An important patent that Astellas has on the urinary incontinence medicine Myrbetriq has been declared invalid by ...
Huma Received FDA Class II clearance for the SaMD platform
Source – HUMA With the FDA’s Class II clearance of its Software as a Medical Device (SaMD) disease management platform, ...
Almirall plans to expand its pipeline with €200 million in capital
Source – Almirall Almirall has completed a €200 million share capital issue, some of which will be used to finalize ...
Valneva Preparing for the FDA’s decision on the chikungunya vaccine
Just a few months away from the FDA making a judgment on Valneva’s marketing application for the chikungunya vaccine VLA1553, ...
